Schirrmacher V, Fogel M, Russmann E, Bosslet K, Altevogt P, Beck L
Cancer Metastasis Rev. 1982;1(3):241-74. doi: 10.1007/BF00046830.
Antigenic variation in cancer metastasis was observed in a syngeneic murine tumor system consisting of a low metastatic parental tumor line (derived from a methylcholanthrene-induced DBA/2 T lymphoma, Eb), a high metastatic spontaneous variant thereof (ESb), and a low metastatic 'revertant' from ESb (ESb-M). All three lines expressed tumor-associated transplantation antigens (TATA) which elicited specific T cell-mediated antitumor immune reactions in the host. The strongest host response was elicited upon intradermal inoculation. It could be followed by (a) the infiltration of the locally growing tumor by host cells, such as lymphocytes and macrophages, (b) the establishment of specific systemic antitumor immunity, (c) the generation of immune cells capable of transferring protective antitumor immunity into a normal syngeneic recipient, and (d) the generation of tumor specific cytotoxic T lymphocytes (CTL). Anti-TATA CTL were used as typing reagents to investigate the stability or variability in the TATA expression by cloned tumor cell lines. Antigenic variability in the TATA expression was seen under various conditions: (a) clone-dependent variation in the sensitivity to anti-TATA CTL lysis upon prolonged growth in tissue culture, (b) qualitative change in the TATA (TATA1 leads to TATA2) upon successive i.p. transplantation of the parental Eb tumor line and, (c) generation of TATA negative immune escape variants (TATA2 leads to TATA-) during metastasis formation from a s.c. site. The relative inefficiency of specific immunization procedures against ESb was found to be due to the effective generation of TATA negative variants by this highly metastatic tumor. The balance between immune control and immune escape could be influenced to the advantage of the host by some means, for instance optimizing the route of antitumor-immune sensitization or by infusion of allogeneic but H-2 identical antitumor-immune T cells. Such immune cells recognized the tumor via minor histocompatibility antigens and thus circumvented the need of TATA recognition. Finally, manipulations at the cell surface of the highly malignant ESb tumor such as those introduced in the ESb-M variant were found to dramatically effect its metastatic potential.
在一个同基因小鼠肿瘤系统中观察到癌症转移中的抗原变异,该系统由一个低转移性亲代肿瘤系(源自甲基胆蒽诱导的DBA/2 T淋巴瘤,Eb)、其高转移性自发变体(ESb)以及ESb的低转移性“回复体”(ESb-M)组成。所有三个系均表达肿瘤相关移植抗原(TATA),这些抗原在宿主体内引发特异性T细胞介导的抗肿瘤免疫反应。皮内接种后引发的宿主反应最强。随后可能会出现:(a)宿主细胞(如淋巴细胞和巨噬细胞)浸润局部生长的肿瘤;(b)建立特异性全身抗肿瘤免疫;(c)产生能够将保护性抗肿瘤免疫转移至正常同基因受体的免疫细胞;(d)产生肿瘤特异性细胞毒性T淋巴细胞(CTL)。抗TATA CTL用作分型试剂,以研究克隆肿瘤细胞系中TATA表达的稳定性或变异性。在各种条件下均观察到TATA表达中的抗原变异性:(a)在组织培养中长时间生长后,对抗TATA CTL裂解的敏感性存在克隆依赖性变异;(b)亲代Eb肿瘤系连续腹腔内移植后,TATA发生定性变化(TATA1转变为TATA2);(c)在皮下部位转移形成过程中产生TATA阴性免疫逃逸变体(TATA2转变为TATA-)。发现针对ESb的特异性免疫程序相对低效是由于这种高转移性肿瘤有效产生了TATA阴性变体。免疫控制与免疫逃逸之间的平衡可以通过某些方式向有利于宿主的方向转变,例如优化抗肿瘤免疫致敏途径或输注同种异体但H-2相同的抗肿瘤免疫T细胞。此类免疫细胞通过次要组织相容性抗原识别肿瘤,从而避免了识别TATA的需求。最后,发现对高度恶性的ESb肿瘤细胞表面进行操作(如引入ESb-M变体中的操作)会显著影响其转移潜能。